AR122328A1 - TIM-3 INHIBITORS AND THEIR USES - Google Patents

TIM-3 INHIBITORS AND THEIR USES

Info

Publication number
AR122328A1
AR122328A1 ARP200102898A ARP200102898A AR122328A1 AR 122328 A1 AR122328 A1 AR 122328A1 AR P200102898 A ARP200102898 A AR P200102898A AR P200102898 A ARP200102898 A AR P200102898A AR 122328 A1 AR122328 A1 AR 122328A1
Authority
AR
Argentina
Prior art keywords
tim
inhibitors
maintenance
subject
aml
Prior art date
Application number
ARP200102898A
Other languages
Spanish (es)
Inventor
K Gary J Vanasse
Lamis Eldjerou
Hans Menssen
Jeffrey Scott
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR122328A1 publication Critical patent/AR122328A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen terapias de mantenimiento que comprenden inhibidores de TIM-3. Las terapias de mantenimiento pueden usarse para tratar afecciones y trastornos cancerosos, que incluyen cánceres hematológicos. Además se divulgan las terapias de mantenimiento que comprenden inhibidores de TIM-3. Reivindicación 1: Una terapia de mantenimiento que comprende un inhibidor de TIM-3 para el uso en el tratamiento de una leucemia mieloide agua (AML) en un sujeto. Reivindicación 2: Un método de tratamiento de una leucemia mieloide agua (AML) en un sujeto, que comprende administrar al sujeto una cantidad eficaz de una terapia de mantenimiento que comprende un inhibidor de TIM-3, de manera de tratar la AML.Maintenance therapies comprising inhibitors of TIM-3 are described. Maintenance therapies can be used to treat cancerous conditions and disorders, including hematologic cancers. Furthermore, maintenance therapies comprising TIM-3 inhibitors are disclosed. Claim 1: A maintenance therapy comprising a TIM-3 inhibitor for use in treating acute myeloid leukemia (AML) in a subject. Claim 2: A method of treating acute myeloid leukemia (AML) in a subject, comprising administering to the subject an effective amount of a maintenance therapy comprising a TIM-3 inhibitor, so as to treat AML.

ARP200102898A 2019-10-21 2020-10-20 TIM-3 INHIBITORS AND THEIR USES AR122328A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962923928P 2019-10-21 2019-10-21

Publications (1)

Publication Number Publication Date
AR122328A1 true AR122328A1 (en) 2022-08-31

Family

ID=83218740

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102898A AR122328A1 (en) 2019-10-21 2020-10-20 TIM-3 INHIBITORS AND THEIR USES

Country Status (1)

Country Link
AR (1) AR122328A1 (en)

Similar Documents

Publication Publication Date Title
AR126205A2 (en) METHODS OF USE OF TUMOR INFILTRATING LYMPHOCYTES IN DOUBLE REFRACTORY MELANOMA
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
AR044007A1 (en) METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
MX2020009773A (en) Combination therapy.
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
MX2020008906A (en) Compounds with ferroptosis inducing activity and methods of their use.
CO2020013600A2 (en) Treatment of hidradenitis suppurativa using jak inhibitors
UY28287A1 (en) COMBINATIONS FOR THE TREATMENT OF DISEASES THAT IMPACT CELLULAR PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS
BR112022016382A2 (en) SPECIFIC TRIPTAMINES FOR USE IN THE TREATMENT OF MOOD DISEASES
MX2020013163A (en) Methods of treating malignant lymphoproliferative disorders.
MX2021010173A (en) Compounds with ferroptosis inducing activity and methods of their use.
MX2019009227A (en) Methods for treating cancer using hsp90 inhibitors.
MX2020001727A (en) Combination therapy.
BR112021020409A2 (en) Combination therapy with anti-bcma antibody and gamma-secretase inhibitor
BR112015026247A2 (en) methods for cancer treatment using tor kinase inhibitor combination therapy
WO2018102687A3 (en) Combination therapy for treating cancer
MX2019013862A (en) Combination therapy.
MX2020008680A (en) Combination therapy with apilimod and glutamatergic agents.
CL2022001878A1 (en) Combination comprising a thym-3 inhibitor and a hypomethylating agent for use in the
CL2023002223A1 (en) CDK2 inhibitors and methods of their use
BR112022007179A2 (en) TIM-3 INHIBITORS AND USES THEREOF
MX2021007330A (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.
MX2021007565A (en) Compositions and methods for cancer therapy.
DOP2021000215A (en) HEADACHE TREATMENT USING ANTI-CGRP ANTIBODY
EA202193276A1 (en) METHODS FOR THE TREATMENT OF CHOLANGIOCARCINOMA